Reconciling the Use of Human Fetal Tissue in Research Authors: Harvey B. Sarnat, William D. Graf, Mark S. Scher, Phillip L. Pearl, Laura Flores‐Sarnat Published: 2026 The recent decision by the U.S. National Institutes of Health (NIH) to discontinue funding for research using human fetal tissue derived from “elective” abortions has major implications for the future of science and health [1, 2]. By halting federal financial support for such studies, the NIH has created major obstacles for researchers seeking to advance knowledge in human development, disease mechanisms, and emerging biomedical technologies. The NIH justified this directive by asserting “the science supports this shift” and “the ethics demand it.” [3] The change in policy infers that human fetal tissue research is technically replaceable and morally problematic due to its association with pregnancy termination. Addressing this issue requires careful consideration of both the scientific importance of human fetal tissue research and the ongoing societal debates about the morality and permissibility of abortion. Biomedical Research Involving Human Fetal Tissue Is Essential Human fetal tissue research is essential for studying normal and anomalous fetal development, modeling infections (such as HIV/AIDS) by creating humanized mouse models in immunodeficient mice to create chimeric animals susceptible to infection, producing pharmaceuticals, and developing vaccines. Compared with mature cells (such as HeLa cells obtained in 1951 from a single adult, Henrietta Lacks), fetal‐derived stem cells are immature, undifferentiated, highly proliferative, less immunogenic, and easier to grow and maintain in culture. Research involving human fetal tissue has a longstanding history. As early as the 1930s, human fetal tissue was used as a source for generating cell lines for medical research. The properties of cell strains such as WI‐38, derived from the lung tissue of a legally aborted fetus in Sweden in 1962, have been used to develop and test lifesaving antiviral vaccines, including those that protect against polio, measles, rubella, rabies, hepatitis A, varicella, shingles, and COVID‐19—all without containing fetal cells [4, 5]. Fetal tissues and cell lines are used to study fetal‐maternal interactions important for pregnancy complications such as preeclampsia, fetal growth restriction, recurrent miscarriage, preterm birth, and fetal malformations, which represent a significant burden on human health. Fetal cell lines and tissues are also used for testing and developing treatments for diabetes, cystic fibrosis, hemophilia, Parkinson's disease, and macular degeneration. Public awareness is crucial for supporting responsible scientific research, continuing ethical access, and achieving better health outcomes. Legally and ethically acquired human fetal tissue has been used to study fetal development in normal controls, malformations, congenital infections, and other adverse pathological events that affect fetal health and maturation. One of our laboratories (HBS) has contributed considerable data relating to the temporal and spatial sequence of synaptogenesis in most structures of the fetal brain and, most recently, to the role of intracerebral proteoglycans (mucopolysaccharides) in the guidance of migratory neuroblasts and axonal pathfinding [6, 7]. These findings could not have been documented by any technique other than direct microscopic examination of fetal brain tissue with special stains and immunoreactivities. Such human fetal tissue studies have broad clinical relevance. Alternative Biomedical Technologies Supplement but Do Not Replace Human Fetal Tissue The new NIH policy promotes organoids, tissue chips, and computational biology as alternatives to fetal tissue [1]. Despite technological progress, satisfactory alternatives for many applications of human fetal tissue research are lacking. Organoids can identify early developmental stages but do not replicate full prenatal development or in vivo maturation of human brain structures. Most animal models are not fully applicable to normal or pathological human maturation. Tissues obtained from miscarriages and stillbirths present challenges for many analytical techniques due to postmortem autolysis, compromising the reliability of immunocytochemical and biochemical findings. Microscopic analysis of fetal tissue continues to provide anatomical detail that surpasses all current neuroimaging techniques. The importance of human fetal tissue research has been stressed by organizations such as the International Society for Stem Cell Research (ISSCR), which urge the NIH to reconsider its decision to ensure progress in biomedical science and the development of innovative therapies [8]. Research Involving Human Fetal Tissue Is Already Tightly Regulated Structured research and tissue procurement networks, acting as registries or repositories, emerged in the United States in the early 1960s. Guidelines for human fetal tissue donation in the U.S. were established in 1975 by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The NIH Revitalization Act of 1993 codified regulations for the procurement of human fetal tissue, requiring informed consent and separating the transplantation process from abortion procedures. Such registries, or tissue suppliers, act as intermediaries to ensure human fetal tissue procurement complies with the Uniform Anatomical Gift Act guidelines and subsequent federal regulations prohibiting its sale for profit [9]. Stillborn registries initially linked multisystemic fetal conditions, including CNS disorders, to health issues within the maternal‐placental‐fetal triad. Human placental registries have since improved insight into pregnancy‐related health and disease pathways affecting brain development. Collaborative efforts among health care professionals, NIH researchers, health policy experts, policymakers, and advocacy organizations have been instrumental in advancing research aimed at reducing fetal mortality, including miscarriage and stillbirth. The new NIH policy distinguishes fetal tissue from miscarriage or stillbirth and fetal tissue obtained after “elective” abortion [1]. Throughout history, there have been widely divergent views about the morality of elective abortions and about the use of fetal tissue derived from such abortions for the purposes of research. The mere classification of some abortions as “elective” is a subject of debate, with varying perspectives informed by technical, ethical, legal, social, and medical definitions (e.g., fetal tissue from ectopic pregnancy) [10]. Accordingly, the term “elective abortion” may be viewed as a moral judgment rather than a medical diagnosis. Many pregnant women endorse fetal tissue donation when given the choice, often seeing it as giving meaning to pregnancy loss or termination [11]. The balance of ethical principles indicates that the use of human fetal tissue should be ethically permissible if robust safeguards are in place, particularly that the decision to donate tissue is entirely separated from the decision to terminate a pregnancy. Current federal law requires that consent for fetal tissue donation occur after the decision to terminate a pregnancy, to avoid any possibility of exploitation or coercion [9]. The consent process should not raise questions about who has authority over fetal tissue disposition—and generally all human fetal tissue donation requires voluntary, informed consent from the parent(s). Defunding HFT Research Will Harm Scientific Progress and Global Health The NIH funding ban will hinder essential research by restricting fetal tissue studies and will negatively impact global public health in all nations. Neurodevelopmental disorders, influenced by complex prenatal gene‐environment interactions, continue to pose a global health challenge, especially in low‐resource regions [12]. Fetal tissue research offers opportunities to develop brain health bundles that apply knowledge of reproductive and pregnancy health to investigate therapeutics that protect the developing fetal brain within the maternal‐placental‐fetal triad. This vital research will contribute to preventative, rescue, and reparative interventions for brain disorders experienced across the lifespan, from developmental disorders and epilepsies to neurodegenerative diseases and stroke. In summary, human fetal tissue research is essential research that has led to major medical advancements and saved millions of lives. Restricting future funding for human fetal tissue research will hinder new discoveries and the development of innovative treatments for various conditions affecting people of all ages throughout the world. Current human fetal tissue research poses no risk to patients or the public. Ethical public policy on human fetal tissue research should maximize the public good, recognize the integrity of science, safeguard the personal health care decisions of pregnant women, and ensure ethical and legal parental informed consent according to current guidelines. Science should remain apolitical, and scientists must help to uphold this view among the public and policymakers [13]. Author Contributions Harvey B. Sarnat: conceptualization, writing – original draft, formal analysis, investigation, writing – review and editing. William D. Graf: conceptualization, writing – original draft, writing – review and editing, formal analysis. Mark S. Scher: writing – review and editing. Phillip L. Pearl: writing – review and editing. Laura Flores‐Sarnat: writing – review and editing. Funding The authors have nothing to report. Conflicts of Interest Dr. Scher reports no conflicts of interests. Dr. Pearl is the senior associate editor of ACNS. Drs. Sarnat, Graf, and Flores‐Sarnat are members of the editorial board of ACNS.